Tag: Biosimilar

Yes, PROCRIT (epoetin alfa) is officially classified as a biologic medication, a complex drug derived from living organisms through recombinant DNA technology. As a recombinant protein, it differs fundamentally from chemically synthesized small-molecule drugs and works by mimicking a natural human hormone.

According to the National Cancer Institute, epoetin alfa is the generic name for a medication with multiple brand names, including Procrit. This means that while they share the same active ingredient, understanding the core relationship and clinical context is key to answering the question: **Are Procrit and epoetin the same?**.

Studies show that Hyrimoz is highly similar to Humira, offering comparable safety, effectiveness, and quality for treating various inflammatory diseases. The key difference lies in Hyrimoz's status as a biosimilar, which allows for a more affordable alternative to the original Humira.

In the United States, patents are expected to protect semaglutide until at least 2031, delaying any true generic availability. This timeline has fueled public discussion around the high costs and the question, **will there be a generic semaglutide**?

Over 2.3 million Canadians aged 40 and over are living with osteoporosis [1.7.1]. For those with severe forms of the disease, a key question is, 'Can I buy Forteo in Canada?' Yes, but only with a valid prescription.

Trulicity (dulaglutide) is a brand-name biologic drug, and for that reason, there is currently no generic for Trulicity. The medication will remain a brand-only product until its patent protections expire, with a potential biosimilar arriving as early as 2027.

According to recent analyses, some biosimilar versions of Hyrimoz can have a list price that is over 80% lower than Humira's list price. This makes answering the question, is Hyrimoz cheaper than Humira, a complex matter that depends heavily on the specific version, insurance coverage, and discount programs available to the patient.

Eylea, a widely prescribed medication for serious retinal conditions, does not have a traditional generic version because it is a biologic drug, not a chemically synthesized one. Its generic, or official reference, name is aflibercept, and with the recent patent expirations, several biosimilar versions are now available, offering new, potentially more affordable, treatment options.

Since 2023, numerous FDA-approved biosimilars have launched in the U.S. market, offering patients and healthcare providers new options following the patent expiration of Humira (adalimumab). This rapid expansion has prompted many to ask: **what is the closest biologic to Humira?** The answer is that several drugs are virtually identical, providing similar safety and efficacy profiles for various autoimmune and inflammatory conditions.

As of late 2024, the U.S. Food and Drug Administration (FDA) has approved Bimzelx (bimekizumab) for multiple conditions, including plaque psoriasis and psoriatic arthritis. However, Bimzelx is a biologic medication, and for that reason, there is currently no generic for Bimzelx.